# Obesitasmanagement bij vrouwen vereist levensfasenspecifieke aanpak

*geplaatst 2026-09-07 · Nierziekte · Obesity pillars · doi 10.1016/j.obpill.2026.100321 · https://hartvaat.nl/2026/09/01/obesitasmanagement-bij-vrouwen-vereist-levensfasenspecifieke-aanpak/*

Dit klinisch overzicht beschrijft hoe obesitas bij vrouwen over de levensloop verschillende gezondheidsrisico’s beïnvloedt, van metabolische dysfunctie in de adolescentie tot een verhoogd cardiovasculair risico in de perimenopauze. Pharmacologische behandelingen, waaronder incretine-agonisten, tonen effectiviteit bij gewichtsreductie en verbetering van het cardiometabole profiel, hoewel levensfasenspecifieke veiligheidsdata nog beperkt zijn. Voor de praktijk betekent dit dat obesitasmanagement bij vrouwen een geïndividualiseerde, levensfaseaanpassende aanpak vereist die lifestyle-interventies en medicatie combineert.

## English: Obesity and Women's health across the lifespan: A clinical review of life Stage-Specific challenges and treatment considerations.

This clinical review outlines how obesity impacts women’s health across the lifespan, highlighting stage-specific risks ranging from early metabolic dysfunction and reproductive complications to increased cardiovascular risk during perimenopause and frailty in older age. Incretin-based pharmacotherapies show proven efficacy for weight loss and cardiometabolic improvement, though life-stage-specific safety and outcome data remain limited. Clinicians should adopt individualized, age- and stage-adapted management strategies that integrate lifestyle modification with appropriate pharmacotherapy.

## Abstract (original, from the publication)

BACKGROUND: Obesity prevalence among females in the United States continues to rise across the lifespan, imposing a substantial burden on individuals and the health care system through an increasing number of preventable, excess weight-attributable disabling diseases and mortality. A clearer understanding of the impact of obesity and treatment interventions on outcomes for reproduction, cardiometabolic risk, musculoskeletal health, and mental health at various life stages is critical to optimizing management strategies for women with obesity. METHODS: This narrative clinical review synthesizes published literature and expert perspectives regarding obesity-related risk factors, health outcomes, and treatment considerations related to obesity in women, including the impact of obesity medications across the lifespan. RESULTS: Adiposity influences reproductive, cardiometabolic, musculoskeletal, and mental health outcomes across the female lifespan. During adolescence, early pubertal onset and metabolic dysfunction are common. In reproductive years, infertility, polyendocrine metabolic ovarian syndrome, and pregnancy complications are prominent. Perimenopause is associated with vasomotor symptoms, sleep disruption, and increased cardiovascular risk. In older age, risks for cancer, functional decline, and frailty increase. Pharmacologic therapies, including incretin-based agents, demonstrate efficacy in weight reduction and cardiometabolic improvement, although life stage-specific safety and outcome data remain limited. CONCLUSION: Obesity management in women requires individualized, life stage-specific approaches integrating lifestyle interventions and pharmacotherapy. Additional research is needed to clarify long-term outcomes and optimize treatment strategies across the lifespan.

Auteurs: Melanie G Cree, Rebecca Dunsmoor-Su, Samar R El Khoudary, Maria Hurtado Andrade, Ekta Kapoor, Genevieve Neal-Perry, Nanette Santoro

---
Bron: Obesity pillars, https://doi.org/10.1016/j.obpill.2026.100321. Bijgewerkt 2026-08-31T01:13:28Z. Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.